Pelthos Therapeutics Inc. Common Stock
Key Metrics
Market Snapshot
About
Pelthos Therapeutics Inc. Common Stock (PTHS) is a biopharmaceutical company that develops and commercializes therapeutic products for patients with unmet treatment needs. Based in Durham, North Carolina, and founded in 2002, it was previously known as Channel Therapeutics Corporation before adopting its current name in July 2025. The company is centered on dermatology and topical treatments for conditions affecting both adults and children.
Pelthos offers several approved products. ZELSUVMI is used to treat molluscum contagiosum, a common skin infection, in adults and children one year of age and older. XEPI, known generically as ozenoxacin cream, is a quinolone antimicrobial for impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in adults and children two months of age and older. XEGLYZE is a pediculicide for the topical treatment of head lice in patients six months of age and older. Together these products address skin and surface infections that often affect young patients.
The company also holds a proprietary technology platform called NITRICIL, which is based on nitric oxide. This platform supports the science behind certain of its treatments and represents an underlying capability that can be applied to product development.
By combining a set of marketed dermatology products with its nitric oxide platform, Pelthos Therapeutics Inc. earns its place in the market through the development and sale of treatments for skin conditions and related infections. Its base in Durham, North Carolina, a recognized center for life sciences, and its history dating to 2002 under an earlier name reflect a company focused on bringing topical therapies to patients who need them.